Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 384,100 shares, an increase of 221.7% from the December 31st total of 119,400 shares. Currently, 2.1% of the company’s shares are sold short. Based on an average trading volume of 493,500 shares, the short-interest ratio is presently 0.8 days.

Hedge Funds Weigh In On Xilio Therapeutics

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after buying an additional 155,337 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Xilio Therapeutics by 18.3% during the second quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock worth $280,000 after acquiring an additional 45,554 shares during the period. Finally, XTX Topco Ltd bought a new stake in Xilio Therapeutics in the 2nd quarter valued at $32,000. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Stock Performance

Shares of XLO stock opened at $0.74 on Wednesday. The firm’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $0.94. The stock has a market cap of $32.52 million, a PE ratio of -0.43 and a beta of -0.25. Xilio Therapeutics has a 52-week low of $0.50 and a 52-week high of $1.93.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. As a group, sell-side analysts predict that Xilio Therapeutics will post -1.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Raymond James dropped their price objective on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.